TNF and inflammatory bowel disease: It has already been shown that protectin D1 treatment decreased leukocyte-endothelial interaction, attenuated neutrophil migration during inflammation and reduced mucosal TNF-α, IL-1β and IL-6, thereby leading to improvements in a IBD murine model.